OncoMatch/Clinical Trials/NCT06612580

68Ga-AAZTA-NI-093 PET/CT: First-in-human Study

Is NCT06612580 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies 68Ga-AAZTA-NI-093 for prostate cancer (adenocarcinoma).

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06612580Data as of Jun 2026Location: China

Treatment: 68Ga-AAZTA-NI-093 — 68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-NI-093 PET/CT in patients with prostate cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

68Ga-AAZTA-NI-093

Cancer type

Prostate Cancer

Demographics

Ages ≤ 80

Male only

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06612580 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 80 years or younger.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Prostate Cancer trials